Skip Navigation LinksHome > March/April 2009 - Volume 15 - Issue 2 > Role of Chemotherapy in Hodgkin’s Lymphoma
Cancer Journal:
doi: 10.1097/PPO.0b013e3181a27018
Special Issue on Hodgkin's Lymphoma: Original Article

Role of Chemotherapy in Hodgkin’s Lymphoma

Seam, Pamela MD*; Janik, John E. MD*; Longo, Dan L. MD†; DeVita, Vincent T. Jr MD‡

Collapse Box

Abstract

The development of curative chemotherapy regimens for the treatment of Hodgkin’s lymphoma (HL) is one of the true success stories in oncology. Most patients diagnosed with HL today can be cured. The major task remaining before us is curing as many patients as possible with their initial therapeutic approach while minimizing the acute toxicities and limiting the lifetime risks of important secondary events such as cardiovascular complications and secondary malignancies. In the 40 years since DeVita et al. developed the mechlorethamine, vincristine, procarbazine, and prednisone chemotherapy regimen, we have learned a great deal about risk stratification to minimize treatment-related toxicity. Positron emission tomography may further assist us in reducing radiation treatment without compromising cures. This review will discuss the development of the chemotherapy regimens used in the management of early and advanced stage HL and the advantages and disadvantages of their use in combination with radiation therapy.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.